Entry Point Capital, LLC Macrogenics Inc Put Options Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
Put Options
0 transactions
Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
---|
Others Institutions Holding MGNX
# of Institutions
154Shares Held
60.6MCall Options Held
218KPut Options Held
259K-
Bellevue Group Ag Kuesnacht, V89.94MShares$32.3 Million0.71% of portfolio
-
Armistice Capital, LLC New York, NY6MShares$19.5 Million0.33% of portfolio
-
Black Rock Inc. New York, NY5.4MShares$17.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.14MShares$13.4 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.31MShares$10.8 Million0.01% of portfolio
About MACROGENICS INC
- Ticker MGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,458,800
- Market Cap $200M
- Description
- MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...